79 related articles for article (PubMed ID: 10094974)
1. Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication.
Polyak SJ; Paschal DM; McArdle S; Gale MJ; Moradpour D; Gretch DR
Hepatology; 1999 Apr; 29(4):1262-71. PubMed ID: 10094974
[TBL] [Abstract][Full Text] [Related]
2. Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis.
François C; Duverlie G; Rebouillat D; Khorsi H; Castelain S; Blum HE; Gatignol A; Wychowski C; Moradpour D; Meurs EF
J Virol; 2000 Jun; 74(12):5587-96. PubMed ID: 10823866
[TBL] [Abstract][Full Text] [Related]
3. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation.
Gale M; Blakely CM; Kwieciszewski B; Tan SL; Dossett M; Tang NM; Korth MJ; Polyak SJ; Gretch DR; Katze MG
Mol Cell Biol; 1998 Sep; 18(9):5208-18. PubMed ID: 9710605
[TBL] [Abstract][Full Text] [Related]
4. Analysis of functional differences between hepatitis C virus NS5A of genotypes 1-7 in infectious cell culture systems.
Scheel TK; Prentoe J; Carlsen TH; Mikkelsen LS; Gottwein JM; Bukh J
PLoS Pathog; 2012; 8(5):e1002696. PubMed ID: 22654662
[TBL] [Abstract][Full Text] [Related]
5. Viral evolution and interferon resistance of hepatitis C virus RNA replication in a cell culture model.
Sumpter R; Wang C; Foy E; Loo YM; Gale M
J Virol; 2004 Nov; 78(21):11591-604. PubMed ID: 15479800
[TBL] [Abstract][Full Text] [Related]
6. Zinc mesoporphyrin induces rapid proteasomal degradation of hepatitis C nonstructural 5A protein in human hepatoma cells.
Hou W; Tian Q; Zheng J; Bonkovsky HL
Gastroenterology; 2010 May; 138(5):1909-19. PubMed ID: 19909748
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C Virus Nonstructural Protein 5A Interacts with Immunomodulatory Kinase IKKε to Negatively Regulate Innate Antiviral Immunity.
Kang SM; Park JY; Han HJ; Song BM; Tark D; Choi BS; Hwang SB
Mol Cells; 2022 Oct; 45(10):702-717. PubMed ID: 35993162
[TBL] [Abstract][Full Text] [Related]
8. RNase L mediates the antiviral effect of interferon through a selective reduction in viral RNA during encephalomyocarditis virus infection.
Li XL; Blackford JA; Hassel BA
J Virol; 1998 Apr; 72(4):2752-9. PubMed ID: 9525594
[TBL] [Abstract][Full Text] [Related]
9. Phospholipid scramblase 1 potentiates the antiviral activity of interferon.
Dong B; Zhou Q; Zhao J; Zhou A; Harty RN; Bose S; Banerjee A; Slee R; Guenther J; Williams BR; Wiedmer T; Sims PJ; Silverman RH
J Virol; 2004 Sep; 78(17):8983-93. PubMed ID: 15308695
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus non-structural 5A protein can enhance full-length core protein-induced nuclear factor-kappaB activation.
Liao QJ; Ye LB; Timani KA; She YL; Yang XJ; Ye L; Wu ZH
World J Gastroenterol; 2005 Nov; 11(41):6433-9. PubMed ID: 16425412
[TBL] [Abstract][Full Text] [Related]
11. Molecular and structural characterization of the domain 2 of hepatitis C virus non-structural protein 5A.
Liang Y; Kang CB; Yoon HS
Mol Cells; 2006 Aug; 22(1):13-20. PubMed ID: 16951545
[TBL] [Abstract][Full Text] [Related]
12. The gamma interferon (IFN-gamma) mimetic peptide IFN-gamma (95-133) prevents encephalomyocarditis virus infection both in tissue culture and in mice.
Mujtaba MG; Patel CB; Patel RA; Flowers LO; Burkhart MA; Waiboci LW; Martin J; Haider MI; Ahmed CM; Johnson HM
Clin Vaccine Immunol; 2006 Aug; 13(8):944-52. PubMed ID: 16893996
[TBL] [Abstract][Full Text] [Related]
13. Virus replication in engineered human cells that do not respond to interferons.
Young DF; Andrejeva L; Livingstone A; Goodbourn S; Lamb RA; Collins PL; Elliott RM; Randall RE
J Virol; 2003 Feb; 77(3):2174-81. PubMed ID: 12525652
[TBL] [Abstract][Full Text] [Related]
14. Analysis for codon usage bias in membrane anchor of nonstructural protein 5A from BVDV.
Gao M; Yang X; Wu Y; Wang J; Hu X; Ma Z; Zhou JH
J Basic Microbiol; 2023 Oct; 63(10):1106-1114. PubMed ID: 37407515
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes.
Romine JL; St Laurent DR; Leet JE; Martin SW; Serrano-Wu MH; Yang F; Gao M; O'Boyle DR; Lemm JA; Sun JH; Nower PT; Huang XS; Deshpande MS; Meanwell NA; Snyder LB
ACS Med Chem Lett; 2011 Mar; 2(3):224-9. PubMed ID: 24900306
[TBL] [Abstract][Full Text] [Related]
16. Sulfur(vi) fluoride exchange as a key reaction for synthesizing biaryl sulfate core derivatives as potent hepatitis C virus NS5A inhibitors and their structure-activity relationship studies.
You Y; Kim HS; Park JW; Keum G; Jang SK; Kim BM
RSC Adv; 2018 Sep; 8(55):31803-31821. PubMed ID: 35548241
[TBL] [Abstract][Full Text] [Related]
17. The Hepatitis C virus NS5A and core proteins exert antagonistic effects on HAMP gene expression: the hidden interplay with the MTF-1/MRE pathway.
Dimitriadis A; Foka P; Kyratzopoulou E; Karamichali E; Petroulia S; Tsitoura P; Kakkanas A; Eliadis P; Georgopoulou U; Mamalaki A
FEBS Open Bio; 2021 Jan; 11(1):237-250. PubMed ID: 33247551
[TBL] [Abstract][Full Text] [Related]
18. Dimer Organization of Membrane-Associated NS5A of Hepatitis C Virus as Determined by Highly Sensitive
Jirasko V; Lends A; Lakomek NA; Fogeron ML; Weber ME; Malär AA; Penzel S; Bartenschlager R; Meier BH; Böckmann A
Angew Chem Int Ed Engl; 2021 Mar; 60(10):5339-5347. PubMed ID: 33205864
[TBL] [Abstract][Full Text] [Related]
19. Baseline Amino Acid Substitutions in the NS5A ISDR and PKR Binding Domain of Hepatitis C and Different Fibrosis Levels and Levels of Development of Hepatocellular Carcinoma in Patients Treated with DAAs.
Paolucci S; Piralla A; Novazzi F; Fratini A; Maserati R; Gulminetti R; Novati S; Barbarini G; Sacchi P; Silvestri A; Baldanti F
Viruses; 2020 Feb; 12(3):. PubMed ID: 32106574
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment.
Muñoz de Rueda P; Fuentes Rodríguez JM; Quiles Pérez R; Gila Medina A; Martín Álvarez AB; Casado Ruíz J; Ruíz Extremera A; Salmerón J
World J Gastroenterol; 2017 Jul; 23(25):4538-4547. PubMed ID: 28740342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
